相似文献
1
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Clin Infect Dis. 2014 Dec 1;59(11):1588-92. doi: 10.1093/cid/ciu682. Epub 2014 Sep 11.
2
Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1.
MAbs. 2015;7(4):681-92. doi: 10.1080/19420862.2015.1038447. Epub 2015 Apr 16.
3
BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.
Lancet Neurol. 2021 Aug;20(8):639-652. doi: 10.1016/S1474-4422(21)00174-5.
4
Detection of JC virus by anti-VP1 immunohistochemistry in brains with progressive multifocal leukoencephalopathy.
Acta Neuropathol. 1997 Sep;94(3):226-31. doi: 10.1007/s004010050697.
5
JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review.
AIDS Res Ther. 2020 Jul 6;17(1):37. doi: 10.1186/s12981-020-00293-0.
6
Capsid protein VP1 deletions in JC virus from two AIDS patients with progressive multifocal leukoencephalopathy.
J Neurovirol. 1995 Jun;1(2):189-94. doi: 10.3109/13550289509113965.
7
Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy.
Neurosci Lett. 1996 Feb 23;205(2):111-4. doi: 10.1016/0304-3940(96)12389-2.
8
Expression of JC virus agnoprotein in progressive multifocal leukoencephalopathy brain.
Acta Neuropathol. 2002 Aug;104(2):130-6. doi: 10.1007/s00401-002-0526-8. Epub 2002 May 24.
9
Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity.
J Infect Dis. 2011 Jul 1;204(1):103-14. doi: 10.1093/infdis/jir198.
10
Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope.
J Immunol. 2002 Jan 1;168(1):499-504. doi: 10.4049/jimmunol.168.1.499.
引用本文的文献
1
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome.
Infez Med. 2025 Sep 1;33(3):333-338. doi: 10.53854/liim-3303-11. eCollection 2025.
2
JC Polyomavirus Infection: A Narrative Review.
Infect Dis Ther. 2025 Sep;14(9):2007-2028. doi: 10.1007/s40121-025-01199-y. Epub 2025 Jul 27.
3
Therapeutic advances in neuroinfectious diseases.
Ther Adv Infect Dis. 2024 Sep 20;11:20499361241274246. doi: 10.1177/20499361241274246. eCollection 2024 Jan-Dec.
4
Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies.
Immune Netw. 2024 Feb 15;24(1):e9. doi: 10.4110/in.2024.24.e9. eCollection 2024 Feb.
5
Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era.
Front Cell Infect Microbiol. 2023 Nov 8;13:1208155. doi: 10.3389/fcimb.2023.1208155. eCollection 2023.
6
Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.
Ther Adv Hematol. 2023 Oct 9;14:20406207231201721. doi: 10.1177/20406207231201721. eCollection 2023.
7
Progressive multifocal leukoencephalopathy 10 years following transplant: 5HT receptor antagonism as an adjunct to immune reconstitution.
BMJ Case Rep. 2022 Dec 13;15(12):e252284. doi: 10.1136/bcr-2022-252284.
8
An Approach to Neurological Disorders in a Kidney Transplant Recipient.
Kidney360. 2020 Jun 16;1(8):837-844. doi: 10.34067/KID.0002052020. eCollection 2020 Aug 27.
9
Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.
J Neurol. 2022 May;269(5):2403-2413. doi: 10.1007/s00415-021-10952-5. Epub 2022 Jan 7.
10
Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab.
Brain Commun. 2021 Dec 16;4(1):fcab292. doi: 10.1093/braincomms/fcab292. eCollection 2022 Feb.
本文引用的文献
1
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
Brain. 2011 Sep;134(Pt 9):2687-702. doi: 10.1093/brain/awr206.
2
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.
J Virol. 2011 Jul;85(14):7256-63. doi: 10.1128/JVI.02506-10. Epub 2011 May 4.
3
Harnessing the biology of IL-7 for therapeutic application.
Nat Rev Immunol. 2011 May;11(5):330-42. doi: 10.1038/nri2970.
4
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.
Cell. 2011 Feb 18;144(4):601-13. doi: 10.1016/j.cell.2011.01.011. Epub 2011 Feb 3.
5
Anti-JC virus antibodies: implications for PML risk stratification.
Ann Neurol. 2010 Sep;68(3):295-303. doi: 10.1002/ana.22128.
6
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Lancet Neurol. 2010 Apr;9(4):425-37. doi: 10.1016/S1474-4422(10)70040-5.
7
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Prostate. 2009 Jun 15;69(9):917-27. doi: 10.1002/pros.20941.
8
Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses.
J Virol Methods. 2006 Jul;135(1):32-42. doi: 10.1016/j.jviromet.2006.01.018. Epub 2006 Mar 9.
9
The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.
J Neurovirol. 2001 Aug;7(4):358-63. doi: 10.1080/13550280152537247.
10
Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.
J Virol. 1999 May;73(5):4465-9. doi: 10.1128/JVI.73.5.4465-4469.1999.
Zotero 插件